Drugs in ATC Class R06AE

Up to Top Level ATC Classes

Up to R - Respiratory system

Up to R06 - ANTIHISTAMINES FOR SYSTEMIC USE

Up to R06A - ANTIHISTAMINES FOR SYSTEMIC USE

Drugs in ATC Class: R06AE - Piperazine derivatives

Tradename	Generic Name
BUCLADIN-S	buclizine hydrochloride
MAREZINE	cyclizine lactate
CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride
CETIRIZINE HYDROCHLORIDE HIVES RELIEF	cetirizine hydrochloride
ZERVIATE	cetirizine hydrochloride

Market Dynamics and Patent Landscape for ATC Class R06AE (Piperazine Derivatives): Set-Point on Exclusivity, Patent Coverage, and Generic/Biosimilar Risk

Last updated: June 19, 2026

ATC R06AE covers antihistamines from the piperazine-derivative class. Patent and market dynamics in this ATC bucket are driven by: (1) which individual active ingredients dominate sales in a given geography, (2) whether the market is anchored by patent-protected branded products or by long-generic penetration, and (3) how formulation and method-of-use IP estates extend Orange Book and/or national phase rights.

However, a complete, decision-grade patent landscape for “ATC Class R06AE” cannot be produced from the information provided in the request alone. R06AE is an ATC class label, not a single drug with an FDA/NDC anchor, Orange Book listing, or known branded product. Without a defined list of covered active ingredients and a specific market (US FDA vs EMA vs national), any attempt to enumerate patents, expiries, Paragraph IV risk, litigation status, or exclusivity would be incomplete and potentially wrong.

No content is provided.